https://www.viviabiotech.com/why-functional-assays-alone-can-miss-drug-mechanisms/https://www.viviabiotech.com/multiple-myeloma-research-the-need-for-functional-profiling-in-a-complex-therapeutic-landscape/https://www.viviabiotech.com/why-leading-pharma-companies-trust-vivia-biotech-for-functional-preclinical-research/https://www.viviabiotech.com/from-animal-models-to-patient-samples-the-regulatory-rise-of-functional-assays-under-the-fda-modernization-act-2-0/https://www.viviabiotech.com/improving-antibodydrug-conjugate-safety-profiling-the-need-for-translational-ex-vivo-models-to-assess-hematotoxicity/https://www.viviabiotech.com/ex-vivo-drug-testing-using-synovial-fibroblasts-from-ra-patients/https://www.viviabiotech.com/the-fda-is-changing-the-rules-of-preclinical-testing-heres-why-patient-based-ex-vivo-assays-matter/https://www.viviabiotech.com/targeting-mrd-functional-profiling-to-guide-the-next-generation-of-therapies-in-hematological-malignancies/https://www.viviabiotech.com/functional-validation-of-a-multispecific-t-cell-engager-in-acute-myeloid-leukemia-using-patient-derived-samples/https://www.viviabiotech.com/when-multi-omics-studies-require-functional-ex-vivo-assays/https://www.viviabiotech.com/ex-vivo-functional-assays-capturing-the-clinical-and-immune-complexity-of-lupus-for-more-predictive-drug-development/https://www.viviabiotech.com/studying-immune-cell-engagers-in-patient-samples/